STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

NAVB NAVIDEA BIOPHARMACEUTICALS INCORPORATED StockScouter® Report

1

StockScouter® Score

NAVIDEA BIOPHARMACEUTICALS INCORPORATED, a micro cap growth company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative
  • The 50-day moving average for NAVB is significantly below its 200-day moving average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 100% done.
Progress: 20% done.
Low
High

Core Model Grades

B
N/A
F
F

Previous Ratings

1
1
3